Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Inclusion Criteria

• •Eligible patients will be aged \>= 18 years. Pediatric patients age 2 years and older will be considered on a case by case basis.
• •Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) according to World Health Organization (WHO) classification or confirmed by hematopathology
• •The patients must be in partial response or better
• •\> 30 days post-transplant without active or chronic infections
• •Karnofsky performance status \>= 60%; Lansky \>= 60
• •Left ventricular ejection fraction (LVEF) \>= institutional lower limit of normal by multigated acquisition (MUGA) scan or echocardiogram within 30 days of first protocol treatment
• •Diffusion capacity of the lung for carbon monoxide (DLCO) \> 40% of predicted value (corrected for hemoglobin) within 3 months of registration
• •Forced expiratory volume in 1 second (FEV1) \> 40% of predicted value within 3 months of registration
• •Forced vital capacity (FVC) \> 40% of predicted value within 3 months of registration
• •Serum creatinine =\< 1.5 mg/dL (133 mmol/L)
• •Serum albumin \>= 3.2 g/dL (or \>= 32 g/L) without IV albumin within the previous 72 hours
• •Bilirubin =\< 1.5 x the upper limit of normal (\[ULN\] except patients with Gilbert syndrome in whom bilirubin level of \> 1.5 x ULN will be allowed)
• •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 times ULN
• •Hemoglobin \>= 8 g/dL with or without transfusion in the last 7 days
• •Absolute neutrophil count (ANC) \>= 1000 without granulocyte colony stimulating factor (GCSF) or granulocyte-macrophage colony-stimulating factor (GMCSF) in the last 2 weeks prior to screening
• •Platelets \>= 50,000micro/mL
• •For allo-HCT, no \>= grade 2 visceral (gut or liver) acute graft versus host disease (GVHD) and no \>= grade 3 or any other acute GVHD (patients with chronic GVHD will be allowed at the discretion of the investigator)
• •Patient agrees to use acceptable contraceptive methods for the duration of time in the study, and to continue to use acceptable contraceptive methods for 2 months after the last tagraxofusp infusion
• •Woman of child bearing potential (WOCBP) with a negative serum or urine pregnancy test within 14 days of tagraxofusp treatment
• •Patient or patient's legal representative, parent(s) or guardian able to sign informed consent
• •The patient can adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment